U.K.-based biotech Alchemab on Tuesday announced a licensing agreement with Eli Lilly (NYSE:LLY) to jointly develop ATLX-1282 ...

The deal builds on an existing research collaboration between Eli Lilly and Alchemab to discover new ALS drugs.

Under terms of the deal, Alchemab will lead early Phase I trials for ATLX-1282 in amyotrophic lateral sclerosis, while Lilly ...

Just four months after Eli Lilly and British biotech Alchemab penned a discovery collaboration, the Big Pharma is licensing ...

Alchemab Therapeutics, a next-gen biopharmaceutical company, has entered into a licensing agreement with Eli Lilly and ...

Privately-held Alchemab Therapeutics, a biotech that uses the power of human immune evolution to identify and develop ...

Financial terms of the new agreement include an upfront payment to secure rights to Alchemab's lead ALS candidate, ATLX-1282, ...

Lilly licenses Alchemab’s ALS antibody ATLX-1282 in $415mn deal, expanding its neuroscience pipeline with a novel, ...

Eli Lilly and Creyon Bio have entered into a partnership worth over $1bn to develop RNA-targeted oligonucleotide (oligo) ...

The deal comes just three months after Lilly and Alchemab Therapeutics partnered to develop new therapies for amyotrophic lateral sclerosis (ALS), a rare neurodegenerative disease for which there is ...